Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin

Journal of Clinical Microbiology

Volumn 48, Issue 3, 2010, Pages 894-899

  Welsh, Kerry J ^a   Abbott, April N ^a   Lewis, Evan M ^a   Gardiner, Jeanelle M ^b   Kruzel, Mark C ^a   Lewis, Cole T ^a   Mohr, John F ^c   Wanger, Audrey ^a   Armitige, Lisa Y ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; PANTON VALENTINE LEUKOCIDIN; RIFAMPICIN; VANCOMYCIN;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; COMORBIDITY; FEMALE; HUMAN; INFANT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEWBORN; POLYMERASE CHAIN REACTION; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TERTIARY HEALTH CARE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DNA FINGERPRINTING; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN; VIRULENCE FACTORS;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 77749255891     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01949-09     Document Type: Article

References (31)

1. Abramson, M. A., and D. J. Sexton. 1999. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect. Control Hosp. Epidemiol. 20:408-411.
2. Boyle-Vavra, S., and R. S. Daum. 2007. Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. Lab. Invest. 87:3-9.
3. Bubeck Wardenburg, J., T. Bae, M. Otto, F. R. Deleo, and O. Schneewind. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med. 13:1405-1406.
4. Campbell, S. J., H. S. Deshmukh, C. L. Nelson, I. G. Bae, M. E. Stryjewski, J. J. Federspiel, G. T. Tonthat, T. H. Rude, S. L. Barriere, R. Corey, and V. G. Fowler, Jr. 2008. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J. Clin. Microbiol. 46:678-684.
5. CLSI. 2006. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S16. CLSI, Wayne, PA.
6. Davis, S. L., M. J. Rybak, M. Amjad, G. W. Kaatz, and P. S. McKinnon. 2006. Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 27:1025-1031.
7. Diep, B. A., and M. Otto. 2008. The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol. 16:361-369.
8. Gasparoni, A., L. Ciardelli, A. Avanzini, A. M. Castellazzi, R. Carini, G. Rondini, and G. Chirico. 2003. Age-related changes in intracellular TH1/TH2 cytokine production, immunoproliferative T lymphocyte response and natural killer cell activity in newborns, children and adults. Biol. Neonate 84:297-303.
9. Gillet, Y., B. Issartel, P. Vanhems, J. C. Fournet, G. Lina, M. Bes, F. Vandenesch, Y. Piemont, N. Brousse, D. Floret, and J. Etienne. 2002. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-759.
10. Gonzalez, B. E., G. Martinez-Aguilar, K. G. Hulten, W. A. Hammerman, J. Coss-Bu, A. Avalos-Mishaan, E. O. Mason, Jr., and S. L. Kaplan. 2005. Severe staphylococcal sepsis in adolescents in the era of community-acquired methicillin-resistant Staphylococcus aureus. Pediatrics 115:642-648.
11. Gonzalez, B. E., A. M. Rueda, S. A. Shelburne III, D. M. Musher, R. J. Hamill, and K. G. Hulten. 2006. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect. Control Hosp. Epidemiol. 27:1051-1056.
12. Hakim, H., J. M. Mylotte, and H. Faden. 2007. Morbidity and mortality of staphylococcal bacteremia in children. Am. J. Infect. Control 35:102-105.
13. Healy, C. M., K. G. Hulten, D. L. Palazzi, J. R. Campbell, and C. J. Baker. 2004. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin. Infect. Dis. 39:1460-1466.
14. Healy, C. M., D. L. Palazzi, M. S. Edwards, J. R. Campbell, and C. J. Baker. 2004. Features of invasive staphylococcal disease in neonates. Pediatrics 114:953-961.
15. Herold, B. C., L. C. Immergluck, M. C. Maranan, D. S. Lauderdale, R. E. Gaskin, S. Boyle-Vavra, C. D. Leitch, and R. S. Daum. 1998. Communityacquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 279:593-598.
16. Hsu, D. I., L. K. Hidayat, R. Quist, J. Hindler, A. Karlsson, A. Yusof, and A. Wong-Beringer. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378-385.
17. Jorgensen, J. H., S. A. Crawford, M. L. McElmeel, and K. R. Fiebelkorn. 2004. Detection of inducible clindamycin resistance of staphylococci in conjunction with performance of automated broth susceptibility testing. J. Clin. Microbiol. 42:1800-1802.
18. Kopp, B. J., D. E. Nix, and E. P. Armstrong. 2004. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann. Pharmacother. 38:1377-1382.
19. Labandeira-Rey, M., F. Couzon, S. Boisset, E. L. Brown, M. Bes, Y. Benito, E. M. Barbu, V. Vazquez, M. Hook, J. Etienne, F. Vandenesch, and M. G. Bowden. 2007. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 315:1130-1133.
20. Lalani, T., J. J. Federspiel, H. W. Boucher, T. H. Rude, I. G. Bae, M. J. Rybak, G. T. Tonthat, G. R. Corey, M. E. Stryjewski, G. Sakoulas, V. H. Chu, J. Alder, J. N. Steenbergen, S. A. Luperchio, M. Campion, C. W. Woods, and V. G. Fowler. 2008. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J. Clin. Microbiol. 46:2890-2896.
21. Lina, G., F. Boutite, A. Tristan, M. Bes, J. Etienne, and F. Vandenesch. 2003. Bacterial competition for human nasal cavity colonization: role of staphylococcal agr alleles. Appl. Environ. Microbiol. 69:18-23.
22. Lina, G., Y. Piemont, F. Godail-Gamot, M. Bes, M. O. Peter, V. Gauduchon, F. Vandenesch, and J. Etienne. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128-1132.
23. Lodise, T. P., J. Graves, A. Evans, E. Graffunder, M. Helmecke, B. M. Lomaestro, and K. Stellrecht. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
24. Maclayton, D. O., K. J. Suda, K. A. Coval, C. B. York, and K. W. Garey. 2006. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin. Ther. 28:1208-1216.
25. Maree, C. L., R. S. Daum, S. Boyle-Vavra, K. Matayoshi, and L. G. Miller. 2007. Community-associated methicillin-resistant Staphylococcus aureus isolates causing healthcare-associated infections. Emerg. Infect. Dis. 13:236-242.
26. Moise, P. A., G. Sakoulas, A. Forrest, and J. J. Schentag. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586.
27. Naimi, T. S., K. H. LeDell, K. Como-Sabetti, S. M. Borchardt, D. J. Boxrud, J. Etienne, S. K. Johnson, F. Vandenesch, S. Fridkin, C. O'Boyle, R. N. Danila, and R. Lynfield. 2003. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290:2976-2984.
28. Neoh, H. M., S. Hori, M. Komatsu, T. Oguri, F. Takeuchi, L. Cui, and K. Hiramatsu. 2007. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 6:13.
29. Sadeghi, K., A. Berger, M. Langgartner, A. R. Prusa, M. Hayde, K. Herkner, A. Pollak, A. Spittler, and E. Forster-Waldl. 2007. Immaturity of infection control in preterm and term newborns is associated with impaired toll-like receptor signaling. J. Infect. Dis. 195:296-302.
30. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
31. Shutt, C. K., J. I. Pounder, S. R. Page, B. J. Schaecher, and G. L. Woods. 2005. Clinical evaluation of the DiversiLab microbial typing system using